Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Neoadjuvant Short-Course/Long-Course Radiotherapy Combined With Anti-PD-1/CTLA-4 Dual Immunotherapy for Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial (RADICAL Trial)

NCT07596290 is registered in ClinicalTrials.gov with Beijing Friendship Hospital as lead sponsor.

NCT NCT07596290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07596290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Neoadjuvant Short-Course/Long-Course Radiotherapy Combined With Anti-PD-1/CTLA-4 Dual Immunotherapy for Locally Advanced Rectal Cancer: A Prospective, Randomized Controlled Trial (RADICAL Trial)
Lead sponsor
Beijing Friendship Hospital
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
July 15, 2026
Completion date
December 31, 2030
Enrollment
342 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal adenocarcinoma, neoadjuvant chemoradiation, neoadjuvant immunotherapy